143 related articles for article (PubMed ID: 38665608)
1. Utility of Visceral Adiposity Index and Lipid Accumulation Products to Define Metabolically-Unhealthy Polycystic Ovary Syndrome in Asian Indian Women - A Cross Sectional Study.
Shreenidhi RA; Mahey R; Rajput M; Cheluvaraju R; Upadhyay AD; Sharma JB; Kachhawa G; Bhatla N
J Hum Reprod Sci; 2024; 17(1):50-57. PubMed ID: 38665608
[TBL] [Abstract][Full Text] [Related]
2. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment.
Amato MC; Guarnotta V; Forti D; Donatelli M; Dolcimascolo S; Giordano C
Hum Reprod; 2013 Jul; 28(7):1919-28. PubMed ID: 23592224
[TBL] [Abstract][Full Text] [Related]
3. Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.
Abruzzese GA; Cerrrone GE; Gamez JM; Graffigna MN; Belli S; Lioy G; Mormandi E; Otero P; Levalle OA; Motta AB
Horm Metab Res; 2017 Jan; 49(1):23-29. PubMed ID: 27571188
[TBL] [Abstract][Full Text] [Related]
4. Lipid Accumulation Product Better Predicts Metabolic Status in Lean Polycystic Ovary Syndrome than that by Visceral Adiposity Index.
Banu H; Morshed MS; Sultana T; Shah S; Afrine S; Hasanat MA
J Hum Reprod Sci; 2022; 15(1):27-33. PubMed ID: 35494190
[TBL] [Abstract][Full Text] [Related]
5. The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) Are Predictors of Insulin Resistance and Hyperandrogenaemia in Obesity/Overweight Women with Polycystic Ovary Syndrome.
Wang H; Cao H; Cao J; Zhang L
Biomed Res Int; 2023; 2023():1508675. PubMed ID: 36814799
[TBL] [Abstract][Full Text] [Related]
6. Visceral Adiposity Index and Lipid Accumulation Product as diagnostic markers of Metabolic Syndrome in South Indians with Polycystic Ovary Syndrome.
Naghshband Z; Kumar L; Mandappa S; Niranjana Murthy AS; Malini SS
J Hum Reprod Sci; 2021; 14(3):234-243. PubMed ID: 34759612
[TBL] [Abstract][Full Text] [Related]
7. Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study.
Ramezani Tehrani F; Minooee S; Azizi F
Eur J Endocrinol; 2014 Aug; 171(2):199-207. PubMed ID: 24816947
[TBL] [Abstract][Full Text] [Related]
8. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
Anik Ilhan G; Yildizhan B; Pekin T
Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
[TBL] [Abstract][Full Text] [Related]
9. The role of the visceral adiposity index in the assessment of metabolic syndrome of polycystic ovary syndrome patients: a new anthropometric index.
Rocha ALL; Baêta T; Nazareth IR; Costa JM; Caporalli JD; Oliveira MA; Couto MG; Azevedo RC; Comim FV; Oliveira FR; Reis FM; Cândido AL
Arch Gynecol Obstet; 2024 Apr; 309(4):1643-1649. PubMed ID: 38321350
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of four surrogate indexes of insulin resistance in middle-aged population in Hefei, China.
Huang R; Cheng Z; Jin X; Yu X; Yu J; Guo Y; Zong L; Sheng J; Liu X; Wang S
Ann Med; 2022 Dec; 54(1):622-632. PubMed ID: 35175162
[TBL] [Abstract][Full Text] [Related]
11. Lipid ratios and obesity indices are effective predictors of metabolic syndrome in women with polycystic ovary syndrome.
Kałużna M; Czlapka-Matyasik M; Kompf P; Moczko J; Wachowiak-Ochmańska K; Janicki A; Samarzewska K; Ruchała M; Ziemnicka K
Ther Adv Endocrinol Metab; 2022; 13():20420188211066699. PubMed ID: 35035875
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome.
Brończyk-Puzoń A; Jagielski P; Kulik-Kupka K; Koszowska A; Nowak J; Zubelewicz-Szkodzińska B
Adv Clin Exp Med; 2017 Aug; 26(5):825-828. PubMed ID: 29068579
[TBL] [Abstract][Full Text] [Related]
13. The Role of Different Methods in Defining Cardiometabolic Risk and Metabolic Syndrome in Women with Polycystic Ovary Syndrome.
Çakır Biçer N; Ermiş AA; Baş D
Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895341
[TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity index and lipid accumulation product index: The promising role in assessing cardiometabolic risk in non-obese patients of PCOS.
Bir A; Ghosh A; Chowdhury S
J Educ Health Promot; 2023; 12():148. PubMed ID: 37404927
[TBL] [Abstract][Full Text] [Related]
15. Comparison of visceral, general and central obesity indices in the prediction of metabolic syndrome in maintenance hemodialysis patients.
Zhou C; Zhan L; Yuan J; Tong X; Peng Y; Zha Y
Eat Weight Disord; 2020 Jun; 25(3):727-734. PubMed ID: 30968371
[TBL] [Abstract][Full Text] [Related]
16. Visceral Adiposity Index, Triglyceride/High-Density Lipoprotein Ratio, and Lipid Accumulation Product Index to Discriminate Metabolic Syndrome Among Adult Type 1 Diabetes Patients.
Karatas S; Beysel S
Metab Syndr Relat Disord; 2021 Nov; 19(9):507-512. PubMed ID: 34283922
[No Abstract] [Full Text] [Related]
17. Lipid accumulation product and visceral adiposity index: two indices to predict metabolic syndrome and insulin resistance in chronic kidney disease patients.
Fahmy AM; El Shall N; Kabbash I; El Ahwal L; Selim A
Endocr Regul; 2023 Jan; 57(1):99-105. PubMed ID: 37183690
[No Abstract] [Full Text] [Related]
18. Clinical surrogate markers for predicting metabolic syndrome in middle-aged and elderly Chinese.
Li R; Li Q; Cui M; Yin Z; Li L; Zhong T; Huo Y; Xie P
J Diabetes Investig; 2018 Mar; 9(2):411-418. PubMed ID: 28664593
[TBL] [Abstract][Full Text] [Related]
19. Body fat indices as effective predictors of insulin resistance in obese/non-obese polycystic ovary syndrome women in the Southwest of China.
Huang X; Wang Q; Liu T; Pei T; Liu D; Zhu H; Huang W
Endocrine; 2019 Jul; 65(1):81-85. PubMed ID: 30924083
[TBL] [Abstract][Full Text] [Related]
20. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]